Your browser is no longer supported. Please, upgrade your browser.
Settings
TCON TRACON Pharmaceuticals, Inc. daily Stock Chart
TCON [NASD]
TRACON Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.35 Insider Own0.40% Shs Outstand29.07M Perf Week8.82%
Market Cap43.02M Forward P/E- EPS next Y-0.43 Insider Trans84.71% Shs Float27.24M Perf Month52.55%
Income-35.00M PEG- EPS next Q-0.23 Inst Own67.20% Short Float1.68% Perf Quarter37.04%
Sales3.00M P/S14.34 EPS this Y-14.10% Inst Trans0.18% Short Ratio0.92 Perf Half Y-34.22%
Book/sh0.72 P/B2.06 EPS next Y52.20% ROA-67.30% Target Price5.35 Perf Year-46.18%
Cash/sh1.35 P/C1.10 EPS next 5Y- ROE-108.00% 52W Range0.50 - 3.20 Perf YTD134.92%
Dividend- P/FCF- EPS past 5Y-14.30% ROI-125.00% 52W High-53.75% Beta3.06
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low196.00% ATR0.15
Employees26 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)63.83 Volatility11.93% 13.93%
OptionableNo Debt/Eq0.30 EPS Q/Q30.50% Profit Margin- Rel Volume0.97 Prev Close1.52
ShortableYes LT Debt/Eq0.25 EarningsFeb 28 AMC Payout- Avg Volume496.36K Price1.48
Recom- SMA2016.86% SMA5038.76% SMA200-13.47% Volume483,345 Change-2.94%
Mar-01-19Reiterated Needham Buy $7
Jun-13-17Reiterated Stifel Buy $14 → $6
Dec-21-16Initiated Jefferies Buy $10
Feb-01-16Resumed Oppenheimer Outperform
Jul-29-15Initiated ROTH Capital Buy $18
Mar-02-15Reiterated Stifel Buy $16 → $20
Mar-02-15Reiterated Oppenheimer Outperform $22 → $26
Feb-24-15Initiated Stifel Buy $16
Feb-24-15Initiated Oppenheimer Outperform $22
Mar-07-19 01:08PM  How Should Investors React To TRACON Pharmaceuticals, Inc.s (NASDAQ:TCON) CEO Pay? Simply Wall St. +8.26%
Mar-01-19 02:30PM  Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 04:02PM  TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-19 04:03PM  TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019 GlobeNewswire +8.23%
Jan-22-19 08:30AM  TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma GlobeNewswire +8.34%
Dec-31-18 07:35AM  Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-27-18 08:35AM  Stocks to Watch Before The Opening Bell on December 27, 2018 ACCESSWIRE +17.34%
07:51AM  The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede Benzinga
Dec-26-18 04:05PM  TRACON Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer GlobeNewswire
08:35AM  TRACON Pharmaceuticals Announces Submission of IND Application for TJ4309 (CD73 Antibody TJD5) for Treatment of Advanced Solid Tumors GlobeNewswire
Dec-21-18 08:10AM  TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma GlobeNewswire -32.02%
Dec-04-18 07:00PM  TRACON Pharmaceuticals and I-Mab Biopharma Reschedule Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs GlobeNewswire
Dec-03-18 08:35AM  TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs GlobeNewswire
Nov-29-18 02:01AM  TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs GlobeNewswire +14.41%
Nov-19-18 08:35AM  TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting GlobeNewswire -6.15%
Nov-15-18 08:35AM  TRACON Pharmaceuticals Presents New Circulating Tumor Cell Data from Ongoing Pivotal Phase 3 TAPPAS Trial of TRC105 and Votrient® in Patients with Angiosarcoma GlobeNewswire
Nov-14-18 09:04AM  Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study PR Newswire -7.75%
Nov-13-18 08:20AM  Factors of Influence in 2018, Key Indicators and Opportunity within Sun Hydraulics, FIS, TRACON Pharmaceuticals, Kona Grill, Endava PLC Sponsored ADR, and Chembio Diagnostics New Research Emphasizes Economic Growth GlobeNewswire
Nov-08-18 12:58PM  Edited Transcript of TCON earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-18 06:54PM  Tracon: 3Q Earnings Snapshot Associated Press
04:02PM  TRACON Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
07:50AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie Benzinga
Oct-31-18 04:02PM  TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018 GlobeNewswire
Oct-15-18 01:00PM  Shareholders Should Check The Ownership Structure Of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Simply Wall St.
Sep-12-18 04:27PM  Edited Transcript of TCON earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 09:00AM  TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC GlobeNewswire
Aug-29-18 04:05PM  TRACON Pharmaceuticals to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-08-18 07:19PM  Tracon: 2Q Earnings Snapshot Associated Press
04:05PM  TRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 04:05PM  TRACON to Report Second Quarter 2018 Company Highlights and Financial Results on August 8, 2018 GlobeNewswire
Jun-13-18 08:00AM  TRACON Announces Presentation of Preclinical Data from Studies of TRC105 in Combination with a PD-1 Antibody in Murine Models of Colorectal Cancer GlobeNewswire
Jun-11-18 12:12PM  Edited Transcript of TCON earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-31-18 04:10PM  TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
04:05PM  TRACON Pharmaceuticals Reports Granting of Inducement Award GlobeNewswire
May-30-18 08:00AM  TRACON Pharmaceuticals Appoints Biotech Industry Veteran Mark Wiggins as Chief Business Officer GlobeNewswire
May-09-18 06:03PM  Tracon: 1Q Earnings Snapshot Associated Press
04:05PM  TRACON Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-02-18 04:05PM  TRACON to Report First Quarter 2018 Company Highlights and Financial Results on May 9, 2018 GlobeNewswire
Apr-09-18 08:00AM  TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors GlobeNewswire
Mar-23-18 08:30AM  TRACON Pharmaceuticals Announces $38.7 Million Private Placement GlobeNewswire -7.41%
Mar-21-18 04:05PM  TRACON Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-06-18 04:05PM  TRACON Pharmaceuticals to Present at 30th Annual ROTH Conference GlobeNewswire
Mar-01-18 01:01PM  Edited Transcript of TCON earnings conference call or presentation 28-Feb-18 9:30pm GMT Thomson Reuters StreetEvents +10.11%
Feb-28-18 06:02PM  Tracon reports 4Q loss Associated Press
04:05PM  TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update GlobeNewswire
12:30PM  TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:20AM  TRACON Pharmaceuticals Q4 Earnings Preview Benzinga
05:55AM  Analysts Expect Breakeven On The Horizon For TRACON Pharmaceuticals Inc (NASDAQ:TCON) Simply Wall St.
Feb-26-18 05:43AM  Did TRACON Pharmaceuticals Incs (NASDAQ:TCON) Recent Earnings Growth Beat The Trend? Simply Wall St.
Feb-21-18 04:05PM  TRACON to Report Fourth Quarter and Full Year 2017 Company Highlights and Financial Results on February 28, 2018 GlobeNewswire
Jan-19-18 10:00AM  TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients GlobeNewswire -8.20%
Jan-18-18 04:05PM  TRACON Pharmaceuticals Reports Granting of Inducement Awards GlobeNewswire
Dec-27-17 11:53AM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : December 27, 2017 Capital Cube
Dec-26-17 08:42AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017 Capital Cube +6.67%
Dec-21-17 06:55AM  TRACON Pharmaceuticals and Ambrx Announce Development and Commercialization Agreement for TRC105 in China GlobeNewswire
Dec-04-17 04:05PM  TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board GlobeNewswire +5.17%
Nov-29-17 04:05PM  TRACON Doses First Patient in Phase 1b Study of TRC105 with Opdivo® in Patients with Lung Cancer GlobeNewswire
Nov-24-17 01:54PM  Edited Transcript of TCON earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-17 04:05PM  TRACON Pharmaceuticals Announces Positive Results from Phase 1 Trial of TRC102 and Fludara® in Patients with Advanced Hematologic Malignancy Published in Oncotarget GlobeNewswire
Nov-09-17 08:00AM  TRACON Pharmaceuticals Presents Updated Data from Phase 1b/2 Study of TRC105 and Votrient® in Patients with Soft Tissue Sarcoma Including Angiosarcoma GlobeNewswire
Nov-07-17 06:08PM  Tracon beats 3Q profit forecasts Associated Press
04:05PM  TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
10:40AM  TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-06-17 04:05PM  TRACON Pharmaceuticals to Present at Upcoming Investment Conferences GlobeNewswire +5.17%
Oct-31-17 04:05PM  TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017 GlobeNewswire
Oct-23-17 11:08AM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 23, 2017 Capital Cube
Oct-15-17 09:00PM  TRACON Pharmaceuticals Announces Multiple TRC105 Poster Presentations at 18th IASLC World Conference on Lung Cancer GlobeNewswire
Oct-06-17 11:07AM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:37AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Sep-07-17 08:00AM  TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma GlobeNewswire +7.46%
Aug-31-17 04:05PM  TRACON Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-16-17 08:00AM  TRACON Pharmaceuticals Announces Positive Results from National Cancer Institute Phase 1/2 Trial of TRC105 and Nexavar® in Hepatocellular Cancer Published in Clinical Cancer Research GlobeNewswire
Aug-09-17 07:11PM  Edited Transcript of TCON earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
03:16PM  Tracon reports 2Q loss Associated Press
Aug-08-17 04:05PM  TRACON Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update GlobeNewswire
10:20AM  Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 04:05PM  TRACON to Report Second Quarter Company Highlights and Financial Results on August 8, 2017 GlobeNewswire
Jul-25-17 08:00PM  Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration GlobeNewswire
Jun-05-17 04:05PM  TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 and TRC102 Studies at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting GlobeNewswire
02:49PM  ETFs with exposure to TRACON Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:59AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-31-17 04:05PM  TRACON Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
May-25-17 04:05PM  TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting GlobeNewswire -6.56%
May-24-17 08:00AM  TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer GlobeNewswire
May-11-17 04:05PM  TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia GlobeNewswire
01:52PM  Edited Transcript of TCON earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 04:20PM  Tracon reports 1Q loss Associated Press
04:05PM  TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update GlobeNewswire
10:15AM  Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-03-17 04:05PM  TRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017 GlobeNewswire
Apr-10-17 04:05PM  TRACON Awarded Most Innovative Trial Design for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards GlobeNewswire
Mar-29-17 04:05PM  TRACON Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire -8.24%
Mar-27-17 04:20PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting GlobeNewswire
Mar-21-17 11:30AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.49%
11:30AM  TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-14-17 05:16PM  TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
04:05PM  TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc., and Santen Pharmaceutical Co., Ltd; a strategic partnership with I-Mab, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
THEUER CHARLESPresident and CEODec 21Buy0.6649,00032,222132,855Dec 21 06:32 PM
Puissance Cross-Border Opportu10% OwnerNov 29Buy1.134,3264,8884,606,094Dec 03 09:39 AM
Viswanathan Ravi10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:54 PM
SANDELL SCOTT D10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:53 PM
Sonsini Peter W.10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:53 PM
BASKETT FOREST10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:51 PM
Florence Anthony A. Jr.10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:51 PM
KERINS PATRICK J10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:52 PM
MOTT DAVID M10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:52 PM
BARRIS PETER J10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:51 PM
New Enterprise Associates 14, 10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:49 PM
BARRETT M JAMES10% OwnerMar 27Buy2.70707,9641,911,5033,466,003Mar 27 04:50 PM